SAN FRANCISCO -- Dual antiangiogenic therapy for previously treated kidney cancer significantly improved progression-free survival (PFS) versus a single drug, a large randomized trial showed.
When outcome selection and prioritisation are defined early in development, the evidence base supports continuity from trial ...
The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a ...
The 59.4% real-world pain responder rate from the use of inFoods® IBS closely mirrors the 59.6% result from the controlled trial-offering an unusual degree of consistency between controlled and ...
The organization presented data aggregated from multiple clinical trials to explore ctDNA's potential as a surrogate endpoint predictive of treatment benefit in lung and other cancers.
CRN’s Security 100 list of the coolest endpoint and managed security companies includes vendors with AI-powered EDR and MDR ...
Explore the evolution of Security Information and Event Management (SIEM) as it integrates AI and machine learning to enhance ...
Ivanti on Tuesday announced patches for over a dozen vulnerabilities in Endpoint Manager (EPM), including issues that were first disclosed in October 2025. In a new advisory, the company warns of a ...
A coordinated reconnaissance campaign targeting Citrix NetScaler infrastructure over the past week used tens of thousands of residential proxies to discover login panels. The activity was observed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results